way 100135 has been researched along with 5-hydroxy-2-n,n-dipropylaminotetralin in 1 studies
| Studies (way 100135) | Trials (way 100135) | Recent Studies (post-2010) (way 100135) | Studies (5-hydroxy-2-n,n-dipropylaminotetralin) | Trials (5-hydroxy-2-n,n-dipropylaminotetralin) | Recent Studies (post-2010) (5-hydroxy-2-n,n-dipropylaminotetralin) |
|---|---|---|---|---|---|
| 143 | 0 | 34 | 42 | 0 | 3 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lima, L; Schmeer, C; Urbina, M | 1 |
1 other study(ies) available for way 100135 and 5-hydroxy-2-n,n-dipropylaminotetralin
| Article | Year |
|---|---|
5HT1A receptor agonist differentially increases cyclic AMP concentration in intact and lesioned goldfish retina. In vitro inhibition of outgrowth by forskolin.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Adenylyl Cyclases; Animals; Cells, Cultured; Colforsin; Cyclic AMP; Dopamine Antagonists; Goldfish; Nerve Crush; Nerve Regeneration; Optic Nerve; Piperazines; Retina; Serotonin Antagonists; Serotonin Receptor Agonists | 1996 |